Your browser is no longer supported. Please, upgrade your browser.
Settings
OTLK Outlook Therapeutics, Inc. daily Stock Chart
OTLK [NASD]
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own2.60% Shs Outstand47.90M Perf Week41.22%
Market Cap92.30M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float33.87M Perf Month48.06%
Income-50.80M PEG- EPS next Q-0.11 Inst Own6.60% Short Float6.26% Perf Quarter34.21%
Sales6.40M P/S14.42 EPS this Y79.70% Inst Trans326.80% Short Ratio2.68 Perf Half Y0.49%
Book/sh-0.43 P/B- EPS next Y7.70% ROA-274.80% Target Price- Perf Year-61.22%
Cash/sh0.05 P/C19.64 EPS next 5Y- ROE274.00% 52W Range0.50 - 2.95 Perf YTD72.88%
Dividend- P/FCF- EPS past 5Y22.80% ROI2576.60% 52W High-65.42% Beta0.28
Dividend %- Quick Ratio0.40 Sales past 5Y-2.10% Gross Margin- 52W Low104.41% ATR0.08
Employees14 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)73.11 Volatility14.23% 9.15%
OptionableNo Debt/Eq- EPS Q/Q62.80% Profit Margin- Rel Volume1.85 Prev Close1.01
ShortableYes LT Debt/Eq- EarningsMay 27 AMC Payout- Avg Volume791.82K Price1.02
Recom1.50 SMA2034.18% SMA5049.81% SMA200-3.29% Volume1,466,757 Change0.99%
Sep-11-19Initiated Ladenburg Thalmann Buy $9
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
May-26-20 08:05AM  Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire +16.33%
May-20-20 08:39AM  Some Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) Estimates Simply Wall St.
May-15-20 08:00AM  Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Apr-21-20 08:05AM  Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors GlobeNewswire -5.61%
Apr-16-20 09:16AM  Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6% Zacks +7.00%
Apr-15-20 08:35AM  Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit GlobeNewswire +7.58%
Apr-14-20 08:05AM  Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2 GlobeNewswire
Mar-19-20 09:32AM  Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98% Simply Wall St. +5.88%
Mar-05-20 08:00AM  Outlook Therapeutics Announces LYTENAVA (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved GlobeNewswire
Feb-26-20 02:26PM  Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market GlobeNewswire -5.45%
Feb-25-20 09:15AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK ACCESSWIRE -8.32%
Feb-24-20 08:00AM  Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market GlobeNewswire -5.61%
Feb-18-20 01:28PM  INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims. GlobeNewswire +6.38%
Feb-14-20 08:00AM  Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020 GlobeNewswire -6.00%
Feb-04-20 08:00AM  Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire
Jan-28-20 08:00AM  Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 GlobeNewswire
Dec-26-19 08:00AM  Outlook Therapeutics Announces Completion of Warrant Restructuring GlobeNewswire
Dec-24-19 07:24AM  The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga -5.24%
Dec-23-19 09:00AM  Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions GlobeNewswire -49.57%
Dec-19-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019 GlobeNewswire
Dec-03-19 08:00AM  Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 GlobeNewswire +53.12%
Nov-13-19 10:44AM  What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)? Simply Wall St. -7.64%
Sep-11-19 08:00AM  Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire +16.64%
Aug-27-19 08:00AM  Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference GlobeNewswire -7.04%
Aug-20-19 08:00AM  Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD GlobeNewswire
Aug-14-19 04:15PM  Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019 GlobeNewswire
Jul-19-19 12:39PM  A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019 Benzinga -6.84%
Jul-18-19 12:05PM  A Look At Benzinga Pro's Most-Searched Tickers For July 18, 2019 Benzinga +34.87%
Jul-16-19 08:00AM  Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD GlobeNewswire
Jun-03-19 08:57AM  Hottest Wall Street Stories: What's Up, What's Down Zacks +7.50%
08:00AM  Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010 GlobeNewswire
May-24-19 12:50PM  A Look At Benzinga Pro's Most-Searched Tickers For May 24 Benzinga +42.35%
May-20-19 09:02AM  Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days MarketWatch +42.86%
May-17-19 03:17PM  Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know Benzinga +37.25%
09:47AM  Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days MarketWatch
May-16-19 09:48AM  Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer MarketWatch +68.06%
May-15-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019 GlobeNewswire -11.62%
Apr-26-19 08:00AM  Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development GlobeNewswire +6.82%
Apr-10-19 09:00AM  Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -45.08%
Apr-01-19 08:00AM  Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010 GlobeNewswire
Mar-15-19 09:00AM  Outlook Therapeutics Announces Reverse Stock Split GlobeNewswire
Mar-05-19 08:00AM  Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements GlobeNewswire -6.49%
Mar-01-19 08:00AM  Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA GlobeNewswire
Feb-14-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019 GlobeNewswire +24.27%
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-01-19 09:15AM  Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement GlobeNewswire
Jan-22-19 09:00AM  Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants GlobeNewswire
Jan-02-19 09:15AM  Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement GlobeNewswire +10.00%
Dec-18-18 09:00AM  Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 GlobeNewswire +14.29%
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BioLexis Pte Ltd.DirectorMar 23Option Exercise0.0029,358,621050,965,058Mar 23 05:35 PM
BioLexis Pte Ltd.DirectorJan 29Option Exercise0.234,657,8521,080,62221,606,437Jan 29 05:53 PM
BioLexis Pte Ltd.DirectorDec 23Option Exercise0.232,909,091674,90916,948,585Dec 30 05:14 PM